A pilot study comparing traumatic stress symptoms by child and parent report across pediatric chronic illness groups.
A pilot study comparing traumatic stress symptoms by child and parent report across pediatric chronic illness groups.
复制标题
DOI:
10.1097/dbp.0b013e3181f17c52
复制
发表时间:
2010-11
期刊:
影响因子:
--
通讯作者:
Janicke DM
中科院分区:
文献类型:
--
作者:
Ingerski LM;Shaw K;Gray WN;Janicke DM
Researchers have recently used a framework of traumatic stress to describe the psychological functioning of children experiencing a chronic illness and their families; however, few studies are available directly comparing symptoms across disease groups. The current study compared traumatic stress symptoms of youth being considered for solid organ and bone marrow transplantation, youth diagnosed with Human Immunodeficiency Virus (HIV), youth diagnosed with sickle cell disease (SCD) and their parents. Correlates of traumatic stress across these populations were also examined. Participants included 64 youth and caregiver dyads with previously scheduled appointments at one of three specialty clinics. Parents completed measures of family demographics, traumatic stress symptoms, and child functional status. Youth (n=45) and parents each completed self-report and parent-proxy measures of youth traumatic stress symptoms. 10% of youth by self-report, 18% of youth by parent-proxy report, and 13% of caregivers described symptoms suggestive of PTSD. Parents of pediatric transplant self-reported greater symptoms than caregivers of youth with HIV and SCD (p<.05). While child functional impairment did not predict child symptoms, a trend was found where parents experiencing more traumatic stress symptoms themselves reported their children experienced greater symptoms by parent-proxy report (p=.07). Findings suggest that while most children and parents across disease groups report sub-clinical levels of traumatic stress symptoms, traumatic stress symptoms may be especially salient for families of pediatric transplant candidates. While interventions are currently available to treat PTSD symptoms, they will likely need to be individualized to meet the needs of specific disease groups.